Patient-Derived Xenograft Model Market Size, Share, Growth by 2030

The market for patient-derived xenograft (PDX) models is anticipated to expand from US$ 378.46 million in 2022 to US$ 975.31 million by 2030, reflecting a compound annual growth rate (CAGR) of 12.6% from 2022 to 2030.

PDX models are laboratory systems developed by transplanting tumor tissues from patients directly into immunocompromised mice. These models are essential for studying tumor biology, evaluating drug effectiveness, and predicting how patients will respond to various therapies. By allowing human tumors to grow in a controlled laboratory environment, researchers can gain insights into cancer behavior and treatment responses. PDX models are particularly valuable in precision oncology, where therapies are customized based on the individual genetic makeup of patients. The growth of the PDX model market is driven by increasing recognition of the benefits of humanized models and the rising demand for personalized medicine. However, the high operational costs associated with PDX models pose a challenge to market expansion.

The advent of CRISPR technology has enabled researchers to create more precise and sophisticated PDX models that closely mimic human disease conditions. This technology allows for rapid and accurate DNA modifications in PDX models, enabling the replication of patient-specific genetic alterations found in various diseases, including cancer. By introducing specific mutations, deletions, or insertions, CRISPR enhances the authenticity of PDX models, facilitating the exploration of genetic factors and mechanisms underlying diseases. With CRISPR-edited PDX models, researchers can deepen their understanding of the roles of specific genes and pathways in tumor development, progression, and treatment responses, leading to valuable insights for personalized therapeutic strategies. Consequently, the integration of CRISPR in biomedical research presents a significant opportunity for the growth of the patient-derived xenograft model market in the years ahead.

Additionally, the increasing collaboration within the industry presents further opportunities for the PDX model market's growth during the forecast period. For example, in July 2022, GemPharmatech entered into a strategic licensing agreement with Charles River Laboratories to exclusively distribute its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. This partnership aims to accelerate the development of innovative therapeutics for various unmet medical needs, particularly in the field of immuno-oncology. As part of the agreement, GemPharmatech provided Charles River with access to its exclusive NCG derivative products for breeding and distribution in designated markets. The NCG derivative product line represents one of the most comprehensive portfolios of immunodeficient research models available. Utilizing NCG-based mice, researchers can enhance preclinical cancer immunotherapy studies through the incorporation of human peripheral blood mononuclear cells, human hematopoietic stem cells, PDX, and immune system reconstitution. Furthermore, Charles River is the sole distributor of NCG mice in North America, and this collaboration broadens the range of NCG models accessible to them. Thus, the patient-derived xenograft model market is poised for future growth.

Application-Based Insights

The patient-derived xenograft model market is divided into several applications, including preclinical drug development, biomarker analysis, translational research, and biobanking. In 2022, the preclinical drug development segment accounted for a substantial share of the market and is projected to experience the highest CAGR from 2022 to 2030. The drug development process typically consists of three primary phases: discovery, preclinical development, and clinical trials. Preclinical development encompasses activities that merge laboratory drug discovery with the initiation of human clinical trials. Animal testing is a critical component of the preclinical phase, as it assesses the efficacy, potency, and adverse drug reactions (ADRs) of potential therapies. Among various animal models, mice are the most commonly used for drug testing; for instance, at Pfizer, 99% of the animals utilized are rats and mice.

End User-Based Insights

The patient-derived xenograft model market is categorized by end users, which include pharmaceutical and biotechnology companies, contract research organizations, and academic and government research institutions. In 2022, academic and government research institutions held the largest share of the market and are expected to register the highest CAGR during the forecast period from 2022 to 2030.

Key sources for the patient-derived xenograft model market report include organizations such as the Breast Cancer Organization, the Centers for Disease Control and Prevention, GLOBOCAN, and the World Health Organization.